Arcxis Biotechnologies, a Pleasanton, California-based biomedical device company, has entered into a financing agreement with IQT, the investment firm that identifies innovative technology solutions to support the missions of the U.S. Intelligence Community.
Arcxis, a venture backed company formed to develop innovative technologies for superior sample processing and pathogen detection accuracy, launched its first products, the ArcPure™ sample preparation kits, in October 2009, and is preparing to launch its automated RNA and DNA sample preparation device, Xisyl™, to the clinical diagnostic marketplace later this year.
This system is aimed to eliminate waste of time in manual sample preparation, as well as provide users with a greater volume of purified starting material for demanding analyses such as organism detection, genotyping, gene expression and PCR.
The company is also developing the BioPhalanx™ analysis workstation, an automated system for improved workflows in the clinical laboratory and other environments.
The investment, which is linked to the latest Arcxis’ funding round led by Claremont Creek Ventures and Kaiser Permanente Ventures, aims to support the company’s development and commercialization efforts.